KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neogenomics (NEO) Long-Term Deferred Tax: 2014-2016

  • Neogenomics' Long-Term Deferred Tax rose 120.06% to $6.5 million in Q4 2016 from the same period last year, while for Dec 2016 it was $6.5 million, marking a year-over-year increase of 120.06%. This contributed to the annual value of $6.5 million for FY2016, which is 120.06% up from last year.
  • Neogenomics' Long-Term Deferred Tax amounted to $6.5 million in Q4 2016, which was up 120.06% from -$32.4 million recorded in Q4 2015.
  • Neogenomics' Long-Term Deferred Tax's 5-year high stood at $6.5 million during Q4 2016, with a 5-year trough of -$32.4 million in Q4 2015.
  • Moreover, its 3-year median value for Long-Term Deferred Tax was $320,000 (2014), whereas its average is -$8.5 million.
  • In the last 5 years, Neogenomics' Long-Term Deferred Tax plummeted by 10,227.81% in 2015 and then skyrocketed by 120.06% in 2016.
  • Over the past 3 years, Neogenomics' Long-Term Deferred Tax (Quarterly) stood at $320,000 in 2014, then slumped by 10,227.81% to -$32.4 million in 2015, then surged by 120.06% to $6.5 million in 2016.
  • Its Long-Term Deferred Tax stands at $6.5 million for Q4 2016, versus -$32.4 million for Q4 2015 and $320,000 for Q4 2014.